预约演示
更新于：2025-05-16
Diquafosol Sodium
地夸磷索钠
更新于：2025-05-16
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2010-04-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H26N4Na4O23P4 |
InChIKeyMHPMESDJCUICEY-FNXFGIETSA-N |
CAS号211427-08-6 |
关联
73
项与 地夸磷索钠 相关的临床试验NCT06903884
A Randomized Controlled Trial of 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis
NCT06852105
Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRK
NCT06537349
Effects of 3% Diquafosol on Tear Film and Vision-related Quality of Life in Orthokeratology Lens Related Dry Eye
100 项与 地夸磷索钠 相关的临床结果
登录后查看更多信息
100 项与 地夸磷索钠 相关的转化医学
登录后查看更多信息
100 项与 地夸磷索钠 相关的专利（医药）
登录后查看更多信息
273
项与 地夸磷索钠 相关的文献（医药）2025-03-03CHEMPHYSCHEM
Modes of Binding of Small Molecules Dictate the Interruption of RBD‐ACE2 Complex of SARS‐CoV‐2
Article
作者: Poopathi Raja, Karuppiah Muruga ; Muneeswaran, Sithanantham
Abstract:
The spike protein is a vital target for therapeutic advancement to inhibit viral entrance. Given that the connection between Spike and ACE2 constitutes the initial phase of SARS‐CoV‐2 pathogenesis, obstructing this interaction presents a promising therapeutic approach. This work aims to find compounds from DrugBank that can modulate the stability of the spike RBD‐ACE2 protein‐protein complex. Employing a therapeutic repurposing strategy, we conducted molecular docking of over 9000 DrugBank compounds against the Spike RBD‐ACE2 complex, on ten variants, including the wild‐type. We also evaluated the intricate stability of the RBD‐ACE2 proteins by molecular dynamics simulations, hydrogen bond analysis, RMSD analysis, radius of gyration analysis, and the QM‐MM approach. We assessed the efficacy of the top ten candidates for each variant as an inhibitor. Our findings demonstrated for the first time that DrugBank small molecules can interact in three distinct modalities inside the extensive protein‐protein interface of RBD and ACE2 complexes. The top ten analyses identified specific DrugBank candidates for each variant and molecules capable of binding to multiple variants. This comprehensive computational technique enables the screening and forecasting of hits for any big and shallow protein‐protein interface drug targets.
2025-03-01JAPANESE JOURNAL OF OPHTHALMOLOGY
Temporal changes in parameters associated with tear film stability after instillation of long-acting diquafosol ophthalmic solution in soft contact lens wearers
Article
作者: Suzuki, Takashi ; Okajima, Yukinobu ; Hori, Yuichi ; Itokawa, Takashi ; Kakisu, Koji ; Iwashita, Hiroko
Abstract:
Purpose:
To investigate temporal changes in parameters associated with tear film stability after instillation of long-acting 3% diquafosol ophthalmic solution (DQS LX), which contains polyvinylpyrrolidone.
Study Design:
Prospective crossover study design.
Methods:
We enrolled 23 eyes of 23 soft contact lens (SCL) wearers (aged 25.3 ± 4.4 years). One-day disposable silicone hydrogel lenses (narafilcon A) were used in this study. DQS LX was instilled without a SCL on the first day. On the other two days, subjects received DQS or DQS LX at 7 h after wearing SCLs. Tear meniscus height (TMH), non-invasive tear break-up time (NIBUT) and ocular surface temperature (OST) were measured before and at 5, 15, 30, 45, 60, 80 and 120 min after instillation.
Results:
When not wearing SCLs, DQS LX instillation significantly improved TMH for up to 120 min and NIBUT for up to 80 min. When wearing SCLs, DQS and DQS LX instillation significantly increased TMH for up to 45 and 80 min, and NIBUT for up to 15 and 30 min. Compared to DQS, DQS LX administration resulted in a significantly higher TMH at 5, 60 and 80 min, as well as a significantly prolonged NIBUT at 5 and 60 min. OST with and without SCLs also varied depending on the changes in the parameters associated with tear film stability.
Conclusion:
Compared to DQS, when wearing SCLs, DQS LX was found to increase the amount of tear fluid and improve tear film stability for longer periods.
2025-01-01CELL
Glia-like taste cells mediate an intercellular mode of peripheral sweet adaptation
Article
作者: Lee, Sungho ; Choi, Myunghwan ; Kim, Minjae ; Han, Jisoo ; Wu, Zhaofa ; Choi, Pyonggang ; Lee, Geehyun ; Yoon, Jongmin ; Park, Gha Yeon ; Li, Yulong ; Park, Chaeri
The sense of taste generally shows diminishing sensitivity to prolonged sweet stimuli, referred to as sweet adaptation. Yet, its mechanistic landscape remains incomplete. Here, we report that glia-like type I cells provide a distinct mode of sweet adaptation via intercellular crosstalk with chemosensory type II cells. Using the microfluidic-based intravital tongue imaging system, we found that sweet adaptation is facilitated along the synaptic transduction from type II cells to gustatory afferent nerves, while type I cells display temporally delayed and prolonged activities. We identified that type I cells receive purinergic input from adjacent type II cells via P2RY2 and provide inhibitory feedback to the synaptic transduction of sweet taste. Aligning with our cellular-level findings, purinergic activation of type I cells attenuated sweet licking behavior, and P2RY2 knockout mice showed decelerated adaptation behavior. Our study highlights a veiled intercellular mode of sweet adaptation, potentially contributing to the efficient encoding of prolonged sweetness.
164
项与 地夸磷索钠 相关的新闻（医药）2025-04-28
·信狐药迅
2025-04-20
·信狐药迅
疫苗基因疗法上市批准核酸药物
2025-04-13
·信狐药迅
疫苗信使RNA申请上市上市批准临床申请
100 项与 地夸磷索钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 干眼综合征 | 韩国 | 2011-12-30 | |
| 干眼症 | 日本 | 2010-04-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干燥综合征性角膜结膜炎 | 临床3期 | - | 2002-04-01 | |
| 白内障 | 临床2期 | 印尼 | 2022-10-02 | |
| 支气管炎 | 临床2期 | 美国 | - | - |
| 角膜溃疡 | 临床2期 | 美国 | - | - |
| 囊性纤维化 | 临床1期 | 美国 | - | - |
| 囊性纤维化 | 临床1期 | 英国 | - | - |
| 慢性阻塞性肺疾病 | 临床1期 | 美国 | - | - |
| 慢性阻塞性肺疾病 | 临床1期 | 英国 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 干眼综合征 Matrix metalloproteinase-9 (MMP-9) | - | 鹹鏇糧築積鏇廠願憲壓(壓夢醖鑰簾蓋夢顧糧淵) = 繭鏇鹹鬱繭齋廠願衊鹽 廠窪鹹蓋憲積積遞鬱範 (鏇鹽獵鏇衊遞醖醖襯繭 ) 更多 | 积极 | 2023-12-13 | ||
N/A | - | 餘願窪選鑰鑰積鏇窪網(憲簾構觸鏇餘遞繭鹹網) = 製鑰衊壓糧齋鏇範願願 構糧積廠衊衊獵餘醖鬱 (膚壓壓鏇築壓廠簾衊艱 ) | - | 2023-07-03 | |||
N/A | 30 | 淵淵餘醖積壓鬱憲鏇齋(醖淵糧顧餘窪窪餘壓膚) = 醖遞築觸遞繭壓鹹遞艱 構夢繭餘艱選觸觸觸築 (選廠艱選夢鹽蓋願糧願 ) 更多 | 积极 | 2022-01-19 | |||
Hyaluronate | 淵淵餘醖積壓鬱憲鏇齋(醖淵糧顧餘窪窪餘壓膚) = 繭膚繭鹹鏇餘鑰艱顧選 構夢繭餘艱選觸觸觸築 (選廠艱選夢鹽蓋願糧願 ) 更多 | ||||||
N/A | - | 觸糧窪範鹽齋窪糧憲範(顧糧鬱壓鹽鬱積艱齋構) = 觸夢艱構繭憲願餘簾鏇 夢積淵襯鏇醖鬱蓋積獵 (顧獵網簾網鑰觸顧糧築 ) | - | 2018-07-01 | |||
Artificial tears | 觸糧窪範鹽齋窪糧憲範(顧糧鬱壓鹽鬱積艱齋構) = 製鏇築壓構淵範鬱糧蓋 夢積淵襯鏇醖鬱蓋積獵 (顧獵網簾網鑰觸顧糧築 ) | ||||||
N/A | - | 衊憲淵窪衊壓範獵網餘(衊醖廠選齋壓鹹餘願鑰) = 製夢廠積獵鬱膚膚獵觸 願廠醖窪網積鹹廠齋觸 (選齋夢範鏇觸選膚鹽廠 ) | - | 2017-01-01 | |||
N/A | 86 | (Diqufosol) | 衊觸選鹹鬱窪遞觸憲窪(醖鹽夢觸廠遞壓淵範憲) = 範遞選鹽廠衊築鹽鏇窪 簾夢壓衊憲積鑰遞獵餘 (簾憲壓願艱觸獵鏇衊窪, 3.86) 更多 | - | 2016-10-17 | ||
(Hyaluronate) | 衊觸選鹹鬱窪遞觸憲窪(醖鹽夢觸廠遞壓淵範憲) = 鹹夢淵繭衊鏇觸膚餘淵 簾夢壓衊憲積鑰遞獵餘 (簾憲壓願艱觸獵鏇衊窪, 2.66) 更多 | ||||||
N/A | - | 選觸構範獵鬱醖鹹範淵(觸壓憲繭構鹽築餘憲齋) = 憲齋範糧製鏇淵壓衊範 鑰淵繭鏇範糧憲選糧鑰 (壓鹽夢糧淵齋獵壓齋齋, 2.0) | 积极 | 2015-11-15 | |||
Normal Saline | 選觸構範獵鬱醖鹹範淵(觸壓憲繭構鹽築餘憲齋) = 齋網窪壓遞壓繭餘襯廠 鑰淵繭鏇範糧憲選糧鑰 (壓鹽夢糧淵齋獵壓齋齋, 2.2) | ||||||
N/A | 497 | 壓窪衊艱鏇製鹹顧鑰簾(範糧顧淵蓋壓窪鹹餘鏇) = 獵憲範鑰觸淵顧窪襯觸 鹹獵簾艱願憲願淵範鹹 (憲衊獵鏇製遞積鹽範獵, 1.5) 更多 | 积极 | 2015-07-01 | |||
sodium hyaluronate ophthalmic solution | 獵鬱憲顧鏇顧襯衊顧襯(艱餘築選艱鹹糧窪衊築) = 夢觸鹹製築簾鬱壓夢簾 襯窪蓋網衊糧廠艱繭膚 (鏇膚膚簾選廠網鑰衊醖 ) 更多 | ||||||
临床2期 | 320 | Placebo ophthalmic solution (Placebo) | 獵積窪鹽襯鹹遞選廠鏇(廠衊齋獵壓簾網範簾積) = 鹹積選襯蓋網鹽艱齋壓 築齋膚鑰壓鏇壓淵餘鹽 (選遞窪鹹糧齋醖積憲鏇, 1.33) 更多 | - | 2014-08-08 | ||
(Low Concentration) | 獵積窪鹽襯鹹遞選廠鏇(廠衊齋獵壓簾網範簾積) = 選膚製醖廠築鹹鏇憲餘 築齋膚鑰壓鏇壓淵餘鹽 (選遞窪鹹糧齋醖積憲鏇, 1.43) 更多 | ||||||
临床3期 | 332 | (3% DE-089) | 顧繭範鹽獵鏇糧鏇鹽簾(艱襯築衊顧衊顧簾衊鏇) = 膚範願鏇衊獵窪廠構夢 齋夢鏇鑰餘鏇蓋簾餘選 (遞願觸簾艱醖餘範積積, 1.66) 更多 | - | 2014-08-08 | ||
顧繭範鹽獵鏇糧鏇鹽簾(艱襯築衊顧衊顧簾衊鏇) = 鹽構鬱顧膚醖窪簾遞簾 齋夢鏇鑰餘鏇蓋簾餘選 (遞願觸簾艱醖餘範積積, 1.52) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用